IMPROVED EFFICACY AND SAFETY OF ZANUBRUTINIB VERSUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN CHINA: A SUBGROUP OF ALPINE

Category Primary study
Conference17th International Conference on Malignant Lymphoma
Year 2023
This article has no abstract
Epistemonikos ID: 8a94ad5a45e1770f212b86d9432160d9467ee47c
First added on: May 18, 2026